HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)

Clinical trial NCT06631326 · COMPLETED

Trial details

NCT number: NCT06631326
Sponsor: First Hospital of China Medical University
Status: COMPLETED
Study type: OBSERVATIONAL

HCC - Hepatocellular Carcinoma Hepatic Arterial Infusion Chemotherapy BCLC Stage C Hepatocellular Carcinoma Lenvatinib PD-1 Inhibitors

Start date: 2021-01-01
Primary completion: 2025-10-22
Enrollment: 244

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.